ibandronate

ibandronate
IUPAC name	(1-hydroxy-3-(methylpentylamino)propylidene)bisphosphonic acid
CAS number	114084-78-5
DrugBank	DB00710
UNII	UMD7G2653W
Synonyms	BM 21.0955

ibandronate is a potent bisphosphonate medication primarily used in the management of osteoporosis and the prevention of skeletal-related events in patients with metastatic bone disease. It functions by inhibiting osteoclast-mediated bone resorption, thereby increasing bone mineral density and reducing fracture risk. Developed by the pharmaceutical company Boehringer Mannheim, which later became part of Roche, it is administered orally or via intravenous injection.

Medical uses

Ibandronate is indicated for the treatment and prevention of postmenopausal osteoporosis in women, significantly reducing the incidence of vertebral fractures. It is also approved for the treatment of osteoporosis in men. In oncology, intravenous ibandronate is used to reduce the risk of skeletal-related events, such as pathologic fracture and spinal cord compression, in patients with solid tumors and bone metastases from breast cancer. Clinical trials, such as those published in the New England Journal of Medicine, have demonstrated its efficacy in increasing bone mineral density at the lumbar spine and hip.

Adverse effects

Common adverse effects associated with oral ibandronate include dyspepsia, esophagitis, and musculoskeletal pain. The intravenous formulation may cause an acute-phase reaction characterized by pyrexia, myalgia, and arthralgia, often after the first infusion. Serious but rare risks include osteonecrosis of the jaw, particularly in cancer patients receiving high-dose therapy, and atypical femoral fracture, as noted in safety communications from the U.S. Food and Drug Administration. Renal impairment is a concern with intravenous dosing, necessitating assessment of creatinine clearance prior to administration.

Pharmacology

Ibandronate exhibits high affinity for hydroxyapatite crystals in bone, where it is selectively taken up by areas of active bone resorption. It inhibits the mevalonate pathway in osteoclasts by blocking the enzyme farnesyl pyrophosphate synthase, leading to disrupted cytoskeletal function and induction of apoptosis. Its pharmacokinetics are characterized by low oral bioavailability, which is significantly reduced by food or beverages, and rapid binding to bone mineral with a very long elimination half-life. The drug is not metabolized and is excreted unchanged by the kidney.

Chemistry

Ibandronate is a nitrogen-containing bisphosphonate, chemically described as (1-hydroxy-3-(methylpentylamino)propylidene)bisphosphonic acid. Its molecular structure features a central carbon atom bonded to two phosphonate groups and a side chain containing a tertiary amine group, which is critical for its potent antiresorptive activity. The compound is typically formulated as its sodium salt, ibandronate sodium, a white crystalline powder that is soluble in water. Its development was part of research efforts at Boehringer Mannheim to optimize the structure-activity relationship of bisphosphonates.

History

Ibandronate was synthesized in the late 1980s by researchers at the German pharmaceutical firm Boehringer Mannheim. Following the acquisition of Boehringer Mannheim by Roche in 1997, clinical development continued. It received its first marketing approval in the European Union in 1996 for the treatment of tumor-induced hypercalcemia. The U.S. Food and Drug Administration approved the oral formulation for postmenopausal osteoporosis in 2003 and the intravenous formulation for the same indication in 2005, based on data from the MOBILE study and other pivotal trials.

Society and culture

Ibandronate is marketed under various brand names including Boniva in the United States and Bondronat in Europe. Its development and marketing involved significant collaboration between Roche and the biotechnology company Genentech. The drug's introduction influenced treatment guidelines from organizations like the National Osteoporosis Foundation and the American Society of Clinical Oncology. Its once-monthly oral dosing regimen was a notable advancement in patient convenience compared to daily bisphosphonates like alendronate.

Category:Drugs